ADD-VANTAGE: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD (clinicaltrials.gov) - Oct 8, 2026 - P3 | N=246 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • Atherosclerosis • Cardiovascular
|